Subscribe To

Price Alert Latest News Economic Calendar News

ACRX / AcelRx: Battered And Bruised But Ready For Recovery In 2022

AcelRx continues to be an abysmal investment as the company's flagship product DSUVIA has struggled to gain traction in the middle of COVID-19 headwinds. The lack of DoD orders are hurting the company's quarterly earnings. Consequently, the share price has been crushed and the company's market. Read More

Demo Live Account See Partner Details

Content Topics

Immunovant

Inc

Imvt

Acelrx

Battered

Bruised

Recovery

Stock

ACRX

Posted: Jan 4 2022, 22:56

Author Name: Seeking Alpha

ACRX News

By Seeking Alpha
August 10, 2023

AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief

By Zacks Investment Research
August 10, 2023

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates

AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares

By Zacks Investment Research
May 10, 2023

AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1

AcelRx Pharmaceuticals (ACRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares t

By Seeking Alpha
March 30, 2023

AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Raffi Asadorian - Chief Fina

By Zacks Investment Research
March 30, 2023

AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the

By PRNewsWire
March 21, 2023

AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023

HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the devel

By Seeking Alpha
November 14, 2022

AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2022 Results - Earnings Call Transcript

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2022 Results Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Raffi Asadorian

By Zacks Investment Research
November 14, 2022

AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.